English Italiano Deutsch France

Directorate Changes-Jan 2018

8 January 2018

Directorate Changes

Scapa Group plc (AIM: SCPA), a global supplier of bonding solutions and manufacturer of adhesive-based products for the Healthcare and Industrial markets, today announces the following directorate changes.

Mr Pierre Guyot will join the Board as an Independent Non-Executive Director with immediate effect, and will also become a member of the Board’s Audit and Risk, Remuneration, and Nominations Committees upon his appointment.  Mr Guyot has over 30 years’ experience in the international healthcare industry and is currently a Director of Permobil AB, Sweden, and Peters Surgical SA, France.  From January 2014 until 31 December 2017, Mr Guyot was a Director of Spineguard SA, France, and from 2007 to 2014, he was the Chief Executive Officer of Mölnlycke Health Care in Sweden. Prior to this, Mr Guyot served in various roles in sales and marketing and EMEA positions with Becton Dickinson, Johnson & Johnson, and Boston Scientific.

Mr Brendan McAtamney will join the Board as an Independent Non-Executive Director with effect from 1 February 2018, and will also become a member of the Board’s Audit and Risk, Remuneration and Nominations Committees with effect from that date.  Mr McAtamney was appointed Chief Executive Officer of UDG Healthcare on 2 February 2016, having served as an executive director since December 2013, and having originally joined UDG as Chief Operating Officer in 2013.  Prior to that, Mr McAtamney has held various senior management positions with Abbott, latterly as Vice President Commercial and Corporate Officer within its Established Pharmaceuticals Division.

Mr Richard Perry, Senior Independent Non-Executive Director, who having served on the Board since 2005, has indicated that he does not intend to offer himself for re-election at the 2018 AGM.

Larry Pentz, Scapa Group Chairman, commented: “We are pleased to welcome Pierre and Brendan to the Board and look forward to leveraging the wealth of knowledge and experience they each bring to their roles.  Although Richard Perry will continue in his role as the Senior Independent Director up until his retirement in July 2018, I would also like to take this opportunity to thank Richard for the advice and support he has given me as Chairman and for his contribution and commitment to the Company and the Board of Directors over the last twelve years.

Composition of Board Committees

The following table sets out the composition, following the implementation of the above appointments, of the Board Committees:-

Committee

Chairman

Members

Nominations

Lawrence Pentz

David Blackwood
Martin Sawkins
Richard Perry
Pierre Guyot1
Brendan McAtamney2

Remuneration

Martin Sawkins

David Blackwood
Richard Perry
Lawrence Pentz
Pierre Guyot1
Brendan McAtamney2

Audit and Risk

David Blackwood

Martin Sawkins
Richard Perry
Lawrence Pentz
Pierre Guyot1
Brendan McAtamney2

1 With effect from 8 January 2018
2 With effect from 1 February 2018

The Company makes the following disclosures in relation to Mr Guyot’s appointment in accordance with Rule 17 of and paragraph (g) of Schedule Two of the AIM Rules for Companies:

1. Director’s full name: Pierre Roger Michel Guyot
    Director’s age: 53 years

2. Other directorships / partnerships held during the last five years, including appointment and, where appropriate, resignation dates: 

Name of Company / Partnership

Date appointed

Date resigned

SC Garonne

25 February 2015

na

BSN Medical

1 August 2015

3 April 2017

Spineguard SA

15 January 2014

31 December 2017

Peters Surgical SA

1 January 2014

na

Permobil AB

3 May 2013

na

Mölnlycke Health Care Ltd

10 July 2007

31 March 2014

MHC UK Ltd

9 July 2007

31 March 2014

SSR Seven Ltd

15 May 2007

na

 
3. Shareholding: Mr Guyot does not hold any shares in the Company.

4. Other information: There is no other information required to be disclosed in relation to Mr Guyot under paragraph (g) of Schedule Two of the AIM Rules for Companies.

The Company makes the following disclosures in relation to Mr McAtamney’s appointment in accordance with paragraph (g) of Schedule Two of the AIM Rules for Companies:

1. Director’s full name: Brendan Patrick McAtamney
    Director’s age: 55 years

2. Other directorships / partnerships held during the last five years, including appointment and, where appropriate, resignation dates: 

Name of Company/Partnership

Date appointed

Date resigned

UDG Healthcare plc

16 December 2013

na

Aquilant Analytical Sciences Ltd 

16 December 2013

na

Aquilant Medical (ROI) Ltd

16 December 2013

na

Aquilant Scientific (ROI) Ltd

16 December 2013

na

UDG Healthcare Ireland Ltd

16 December 2013

na

UDG Healthcare Ayrtons (Dublin) Ltd

16 December 2013

na

Aquilant Ltd

30 October 2013

na

Aquilant Scientific (UK) Ltd

30 October 2013

na

Ashfield Healthcare Ltd

3 February 2016

na

Unitech Equipment Ltd

30 October 2013

na

UDG Healthcare (UK) Holdings Ltd

1 June 2015

na

Abbott Laboratories GmbH

31 May 2010

31 July 2013

Abbott Products GmbH

31 May 2010

31 July 2013

Abbott Laboratories

28 February 2010

31 July 2013

Abbott Laboratories Inc

28 February 2010

31 July 2013

Laboratoires Fournier S.A.S

31 May 2010

8 January 2013

Abbott Truecare Pharma Private Ltd

31 May 2010

31 July 2013

3. Shareholding: Mr McAtamney does not hold any shares in the Company.

4. Other information: There is no other information required to be disclosed in relation to Mr McAtamney under paragraph (g) of Schedule Two of the AIM Rules for Companies.

For further information: 
Scapa Group plc:
Wendy Baker                                                                                              +44 (0) 161 301 7400
Group General Counsel and Company Secretary 

Numis Securities Limited:                                                                            +44 (0) 20 7260 1000
Mark Lander
Richard Thomas (Nominated Adviser)

 
   

   « back